Biocompatible Polymer Blends of Poly(D,L-lactic acid-co-glycolic acid) and Triblock PCL-PDMS-PCL Copolymers: Their Characterizations and Degradations

Polymer blends of poly(D,L-lactic-co-glycolic acid), PDLLGA, and triblock polycaprolactonepoly(dimethylsiloxane)-polycaprolactone (PCL-PDMS-PCL) copolymer, TEGOMER, were obtained by coprecipitation from their chloroform mixed solutions into methanol and were characterized by differential scanning calorimetry (DSC), Fourier transform infrared (FTIR), degradation tests and scanning electron microscopy (SEM). Binary blends of PDLLGA/TEGOMER were found to be partially miscible according to DSC measurements and FTIR analysis. Stressstrain results showed that addition of TEGOMER improved significantly the overall toughness of PDLLGA. Degradation of PDLLGA/TEGOMER blends was investigated in phosphate buffered saline at pH = 7.4 and 37 °C, and the morphology of the blends during degradation was examined by scanning electron microscopy

Biocompatible Polymer Blends of Poly(D,L-lactic acid-co-glycolic acid) and Triblock PCL-PDMS-PCL Copolymers: Their Characterizations and Degradations

Polymer blends of poly(D,L-lactic-co-glycolic acid), PDLLGA, and triblock polycaprolactonepoly(dimethylsiloxane)-polycaprolactone (PCL-PDMS-PCL) copolymer, TEGOMER, were obtained by coprecipitation from their chloroform mixed solutions into methanol and were characterized by differential scanning calorimetry (DSC), Fourier transform infrared (FTIR), degradation tests and scanning electron microscopy (SEM). Binary blends of PDLLGA/TEGOMER were found to be partially miscible according to DSC measurements and FTIR analysis. Stressstrain results showed that addition of TEGOMER improved significantly the overall toughness of PDLLGA. Degradation of PDLLGA/TEGOMER blends was investigated in phosphate buffered saline at pH = 7.4 and 37 °C, and the morphology of the blends during degradation was examined by scanning electron microscopy

Controlled release of imatinib mesylate from PLGA microspheres inhibit craniopharyngioma mediated angiogenesis

Poly(lactic-co-glycolic acid) microspheres loaded with imatinib mesylate has been developed as a new therapeutic strategy to prevent craniopharyngioma recurrence. Microspheres composed of different lactic/glycolic acid ratios, molecular weights and drug compositions were synthesized and loaded with imatinib mesylate by modified double-emulsion/solvent evaporation technique and subsequently characterized by particle-size distribution, scanning electron microscopy, encapsulation efficiency and in vitro drug release. Inhibitory potential of imatinib containing microspheres on tumor neovascularization was investigated on craniopharyngioma tumor samples by rat cornea angiogenesis assay. Results showed that microspheres in different LA:GA ratios [LA:GA 50:50 (G50), 75:25 (G25), 85:15 (G15)] considerably reduced neovascularization induced by recurrent tumor samples in an in vivo angiogenesis assay (P < 0.01). Our data indicate that local delivery of imatinib mesylate to the post-surgical tumoral cavity using biodegradable microspheres may be a promising biologically selective approach to prevent the recurrence of craniopharyngiomas, via inhibition of neovascularization